Ku, Geoffrey Yuyat

Publications

Sort by

Co-Author Network

selected publications

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 188
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. The oncologist. 2019 Academic Article GET IT
Times cited: 9
Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?. Annals of surgery. 2019 Letter GET IT
Times cited: 2
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 10
Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma. 2019 GET IT
Times cited: 213
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer discovery. 2018 Academic Article GET IT
Times cited: 98
Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2018 Academic Article GET IT
Times cited: 3
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018 Academic Article GET IT
Times cited: 14
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC cancer. 2018 Academic Article GET IT
Times cited: 56
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA oncology. 2018 Comment GET IT
Times cited: 1120
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 214
The Current Status of Immunotherapies in Esophagogastric Cancer. Surgical oncology clinics of North America. 2017 Review GET IT
Times cited: 4
Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. Surgical oncology clinics of North America. 2017 Review GET IT
Times cited: 4
Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of gastrointestinal oncology. 2016 Academic Article GET IT
Times cited: 22
Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. 2016 Academic Article GET IT
Times cited: 26
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British journal of cancer. 2015 Academic Article GET IT
Times cited: 15
Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2015 Academic Article GET IT
Times cited: 20
Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Comment GET IT
Times cited: 7
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PloS one. 2015 Academic Article GET IT
Times cited: 35
Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 24
Emerging mAbs for the treatment of esophagogastric cancer. Expert opinion on emerging drugs. 2014 Review GET IT
Times cited: 1
Management of gastric cancer. Current opinion in gastroenterology. 2014 Review GET IT
Times cited: 18
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. American journal of clinical oncology. 2014 Academic Article GET IT
Times cited: 7
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Annals of surgical oncology. 2013 Academic Article GET IT
Times cited: 22
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. Journal for immunotherapy of cancer. 2013 Academic Article GET IT
Times cited: 11
Adjuvant (postoperative) therapy for esophageal cancer. Thoracic surgery clinics. 2013 Review GET IT
Times cited: 13
Depression, cytokines, and pancreatic cancer. Psycho-oncology. 2013 Academic Article GET IT
Times cited: 68
Emerging tyrosine kinase inhibitors for esophageal cancer. Expert opinion on emerging drugs. 2013 Review GET IT
Times cited: 11
Chemotherapeutic options for gastroesophageal junction tumors. Seminars in radiation oncology. 2013 Review GET IT
Times cited: 8
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. The Lancet. Oncology. 2012 Review GET IT
Times cited: 62
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer chemotherapy and pharmacology. 2012 Review GET IT
Times cited: 32
Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointestinal cancer research : GCR. 2012 Academic Article GET IT
Times cited: 63
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2011 Academic Article GET IT
Times cited: 64
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung cancer (Amsterdam, Netherlands). 2011 Review GET IT
Times cited: 60
Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series. 2010 GET IT
Times cited: 2
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. 2010 GET IT
Times cited: 20
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 366
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Academic Article GET IT
Times cited: 373
Esophagogastric cancer: targeted agents. Cancer treatment reviews. 2010 Review GET IT
Times cited: 51
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. 2010 GET IT
Times cited: 26
Role of neoadjuvant therapy for esophageal adenocarcinoma. Surgical oncology clinics of North America. 2009 Review GET IT
Times cited: 11
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer immunity. 2009 Academic Article GET IT
Times cited: 79
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation. 2009 Academic Article GET IT
Times cited: 1
Preoperative therapy for esophageal cancer. Gastroenterology clinics of North America. 2009 Academic Article GET IT
Times cited: 12
Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy. 2009 GET IT
Times cited: 9
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009 Academic Article GET IT
Times cited: 33
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 293
Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert review of anticancer therapy. 2008 Review GET IT
Times cited: 3
Preoperative therapy in esophageal cancer. Clinical advances in hematology & oncology : H&O. 2008 Review GET IT
Times cited: 6
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer chemotherapy and pharmacology. 2008 Academic Article GET IT
Times cited: 42
Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 95
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Letter GET IT
Times cited: 16
Esophageal cancer: adjuvant therapy. Cancer journal (Sudbury, Mass.). 2007 Review GET IT
Times cited: 13

more ...

less ...

Background

education and training

M.D., University of Pennsylvania School of Medicine 2002
M.B.A., University of South Australia (Australia) 1997
B.A., Stanford University 1995

Contact

full name

Geoffrey Yuyat Ku

VIVO Weill Cornell Medical College

Geoffrey Yuyat Ku Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name